NEW YORK, April 21, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at XBiotech, Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT).
The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically, after market close on April 20, 2017, the Company announced that the European Medicines Agency rendered a negative trend vote after meeting with the Company to discuss the Company's marketing authorization application for its candidate antibody for the treatment of colorectal cancer. The negative trend vote indicates that it is unlikely that the Committee for Medicinal Products for Human Use will vote in favor of the marketing authorization application at its formal decision vote.
Following this news, shares of XBiotech significantly declined, causing harm to investors.
Request more information now by clicking here: www.faruqilaw.com/XBIT. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
Faruqi & Faruqi, LLP also encourages anyone with information regarding XBiotech's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xbiotech-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-investing-in-xbiotech-inc-to-contact-the-firm-300443745.html
SOURCE Faruqi & Faruqi, LLP